东亚药业
(605177)
| 流通市值：22.48亿 | | | 总市值：22.69亿 |
| 流通股本：1.14亿 | | | 总股本：1.15亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 608,956,060.71 | 466,139,228.82 | 264,569,472.69 | 940,185,710.07 |
| 营业总成本 | 743,356,421.59 | 531,028,171.96 | 292,086,877.75 | 1,003,397,048.89 |
| 其他经营收益 | | | | |
| 营业利润 | -210,893,895.64 | -123,276,857.89 | -34,748,999.57 | -84,607,213.7 |
| 利润总额 | -213,469,741.01 | -126,146,955.87 | -35,275,320.03 | -88,573,147.52 |
| 净利润 | -197,434,671.39 | -118,376,942.74 | -35,201,658.01 | -82,432,149.13 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | -197,434,671.39 | -118,376,942.74 | -35,201,658.01 | -82,432,149.13 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 910,720,478.24 | 976,391,224.51 | 1,113,603,333.32 | 1,193,453,198.54 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,036,698,902.01 | 2,091,716,042.19 | 2,124,190,250.41 | 2,144,479,560.22 |
| 资产总计 | 2,947,419,380.25 | 3,068,107,266.7 | 3,237,793,583.73 | 3,337,932,758.76 |
| 流动负债: | | | | |
| 流动负债合计 | 447,344,254.29 | 495,785,547.41 | 596,660,046.91 | 690,889,675.51 |
| 非流动负债: | | | | |
| 非流动负债合计 | 874,995,071.99 | 868,852,346.14 | 866,944,541.14 | 841,105,628.1 |
| 负债合计 | 1,322,339,326.28 | 1,364,637,893.55 | 1,463,604,588.05 | 1,531,995,303.61 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,625,080,053.97 | 1,703,469,373.15 | 1,774,188,995.68 | 1,805,937,455.15 |
| 股东权益合计 | 1,625,080,053.97 | 1,703,469,373.15 | 1,774,188,995.68 | 1,805,937,455.15 |
| 负债和股东权益合计 | 2,947,419,380.25 | 3,068,107,266.7 | 3,237,793,583.73 | 3,337,932,758.76 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 466,626,864.28 | 360,254,758.38 | 186,499,468.7 | 751,274,707.27 |
| 经营活动现金流出小计 | 402,948,480.38 | 308,440,765.22 | 154,365,530.52 | 1,020,130,703.23 |
| 经营活动产生的现金流量净额 | 63,678,383.9 | 51,813,993.16 | 32,133,938.18 | -268,855,995.96 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 607,060,047.48 | 355,814,850.47 | 131,641,646.57 | 865,841,235.18 |
| 投资活动现金流出小计 | 578,878,411.05 | 304,715,028.75 | 79,983,543.96 | 1,002,156,035.04 |
| 投资活动产生的现金流量净额 | 28,181,636.43 | 51,099,821.72 | 51,658,102.61 | -136,314,799.86 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 83,564,257.64 | 41,700,000 | 19,800,000 | 428,648,239.59 |
| 筹资活动现金流出小计 | 215,822,786.6 | 132,761,015.66 | 41,671,243.64 | 268,965,956.59 |
| 筹资活动产生的现金流量净额 | -132,258,528.96 | -91,061,015.66 | -21,871,243.64 | 159,682,283 |
| 汇率变动对现金及现金等价物的影响 | -1,144,184.43 | -790,630.77 | -347,708.98 | 1,128,906.78 |
| 现金及现金等价物净增加额 | -41,542,693.06 | 11,062,168.45 | 61,573,088.17 | -244,359,606.04 |
| 期末现金及现金等价物余额 | 202,423,667.17 | 255,028,528.68 | 305,539,448.4 | 243,966,360.23 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 11,062,168.45 | - | -244,359,606.04 |